

Special Issue

Targeted Drugs in Chronic Lymphocytic Leukemia

Message from the Guest Editors

Over the past decade the treatment of CLL has transformed with the emergence of novel targeted therapies. Recent clinical advances have successfully tested newer generation drugs and combination therapies. We are pleased to invite you to submit to this Special Issue on Targeted Drugs in Chronic Lymphocytic Leukemia. We are interested in receiving high-quality articles including basic, translational, and clinical studies. This Special Issue aims to highlight the importance of the use of currently available targeted therapies in CLL as well as research on the development of new agents and basic research into novel targetable pathways. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: Kinase targeted agents (BTK, PI3K, SYK), BCL2-family targeted agents, other small molecules, monoclonal antibodies, antibody-drug conjugates, bi-specific antibodies, and immunotherapies, including CAR-T cell therapies. Please spread the word to all of your colleagues! We look forward to receiving your contributions.

Guest Editors

Dr. Justin Taylor

Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA

Dr. Anthony Mato

Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Deadline for manuscript submissions

closed (1 March 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/104413

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)